Achieve Life Sciences, Inc. (ACHV) Stock AnalysisACHVAchieve Life Sciences, Inc.

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Achieve Life Sciences is a good buy right now due to its current price of $6.38, which is significantly below the analyst consensus target price of $14.11, suggesting an upside of 83.48%. Additionally, the stock's RSI of 18.54 indicates it is oversold, potentially offering a buying opportunity. The main risk is its negative earnings per share (EPS) of -0.28 reported in the last quarter, which reflects ongoing financial challenges.

1 analysts cover ACHV: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 15.50.